| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.10.23 | Harpoon Therapeutics Inc.: Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 | 226 | GlobeNewswire (Europe) | Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in... ► Artikel lesen | |
| 21.10.23 | Regeneron Pharmaceuticals, Inc.: Libtayo (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC) | 324 | GlobeNewswire (Europe) | 89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial No disease recurrence among the 51% of patients... ► Artikel lesen | |
| 21.10.23 | ORIC Pharmaceuticals: Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile | 222 | GlobeNewswire (Europe) | CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic... ► Artikel lesen | |
| 21.10.23 | Immunocore Holdings Limited: Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial | 1.447 | GlobeNewswire (Europe) | Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023
KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01... ► Artikel lesen | |
| 21.10.23 | F2G, Ltd.: F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim | 722 | GlobeNewswire (Europe) | An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteriaThe success rate rose to 75.2%... ► Artikel lesen | |
| 21.10.23 | LumiraDx Inc: LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub | 1.352 | GlobeNewswire (Europe) | Made possible thanks to unrestricted grant funding from AstraZeneca and run by the official charity of Everton Football Club - Everton in the Community - the Liverpool-based hub will provide significant... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 3.270 |
| EVOTEC | 2.614 |
| TUI | 2.060 |
| NEL | 1.316 |
| BAYER | 1.132 |
| PLUG POWER | 1.125 |
| NVIDIA | 1.114 |
| RHEINMETALL | 1.043 |
| AMC ENTERTAINMENT | 1.029 |
| DEUTSCHE BANK | 937 |
| SIEMENS ENERGY | 922 |
| RENK GROUP | 868 |
| REDCARE PHARMACY | 719 |
| COMMERZBANK | 718 |
| HEIDELBERGER DRUCK | 698 |
| ALIBABA | 671 |
| VOLKSWAGEN | 665 |
| E.ON | 607 |
| BARRICK GOLD | 602 |
| BYD | 583 |
| RWE | 577 |
| SIEMENS | 559 |
| AIXTRON SE | 551 |
| TESLA | 551 |
| SFC ENERGY | 549 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
